About Ancora Heart
Ancora Heart is a company based in San Francisco (United States) founded in 2001.. Ancora Heart has raised $151.26 million across 4 funding rounds from investors including Sio Capital Management, Sands Capital Ventures and Savitr Capital. Ancora Heart offers products and services including AccuCinch Ventricular Restoration System. Ancora Heart operates in a competitive market with competitors including Sequana Medical, CVRx, HeartWare, Element Science and SynCardia, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Guided Delivery Systems, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$151.26 M (USD)
in 4 rounds
-
Latest Funding Round
$80 M (USD), Series D
Jul 19, 2021
-
Investors
Sio Capital Management
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ancora Heart
Ancora Heart offers a comprehensive portfolio of products and services, including AccuCinch Ventricular Restoration System. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative therapy for heart failure to improve patient quality of life.
Unlock access to complete
Funding Insights of Ancora Heart
Ancora Heart has successfully raised a total of $151.26M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $80 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series D — $80.0M
-
First Round
First Round
(28 Apr 2010)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Series D - Ancora Heart | Valuation | Sio Capital Management , Sands Capital Ventures |
|
| Dec, 2018 | Amount | Series C - Ancora Heart | Valuation |
investors |
|
| May, 2018 | Amount | Series B - Ancora Heart | Valuation | Savitr Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ancora Heart
Ancora Heart has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Sio Capital Management, Sands Capital Ventures and Savitr Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth stage tech & life sciences focused VC Firm investing in Asia and the US
|
Founded Year | Domain | Location | |
|
Savitr Capital is focused on direct capital investments.
|
Founded Year | Domain | Location | |
|
Global hedge fund managing equity market neutral investments in the healthcare sector.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ancora Heart
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ancora Heart
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ancora Heart Comparisons
Competitors of Ancora Heart
Ancora Heart operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sequana Medical, CVRx, HeartWare, Element Science and SynCardia, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Implantable battery-powered pumps for ascites removal are developed.
|
|
| domain | founded_year | HQ Location |
Implantable technology for hypertension and heart failure is developed.
|
|
| domain | founded_year | HQ Location |
Miniaturized ventricular assist devices are developed for heart failure treatment.
|
|
| domain | founded_year | HQ Location |
Wearable patch defibrillators are developed for sudden cardiac arrest treatment.
|
|
| domain | founded_year | HQ Location |
Total artificial hearts are developed for cardiac replacement therapy.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ancora Heart
Frequently Asked Questions about Ancora Heart
When was Ancora Heart founded?
Ancora Heart was founded in 2001 and raised its 1st funding round 9 years after it was founded.
Where is Ancora Heart located?
Ancora Heart is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Ancora Heart a funded company?
Ancora Heart is a funded company, having raised a total of $151.26M across 4 funding rounds to date. The company's 1st funding round was a Series B of $17.8M, raised on Apr 28, 2010.
What does Ancora Heart do?
Ancora Heart (formerly known as Guided Delivery Systems- before Sep 2016) develops the percutaneous AccuCinch Ventriculoplasty System for the minimally invasive treatment of heart failure and functional mitral regurgitation (FMR). The company is covered by the following US patents- 8,44; 8,4; 8; 8,821,518; 9,011; and 9,211. The company is for use under the US patents- 8.5; 8.6; and 8.9. The company is funded by Savitr Capital. As of Dec 2016, the AccuCinch System is undergoing clinical trials and is not yet available for sale.
Who are the top competitors of Ancora Heart?
Ancora Heart's top competitors include Sequana Medical, CVRx and Adona Medical.
What products or services does Ancora Heart offer?
Ancora Heart offers AccuCinch Ventricular Restoration System.
Who are Ancora Heart's investors?
Ancora Heart has 3 investors. Key investors include Sio Capital Management, Sands Capital Ventures, and Savitr Capital.